Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LAG-3: from molecular functions to clinical applications
Takumi Maruhashi, Daisuke Sugiura, Il‐mi Okazaki, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001014-e001014
Open Access | Times Cited: 360

Showing 1-25 of 360 citing articles:

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Lukas Kraehenbuehl, Chien‐Huan Weng, Shabnam Eghbali, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 1, pp. 37-50
Closed Access | Times Cited: 582
Glioma targeted therapy: insight into future of molecular approaches
Keyang Yang, Zhijing Wu, Hao Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 476
Immune checkpoint therapy—current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1652-1669
Closed Access | Times Cited: 441
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
Alexander C. Huang, Roberta Zappasodi
Nature Immunology (2022) Vol. 23, Iss. 5, pp. 660-670
Open Access | Times Cited: 376
Immunotherapy: Reshape the Tumor Immune Microenvironment
Bingzhe LV, Yunpeng Wang, Dongjiang Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 253
Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
An‐Ping Shi, Xiyang Tang, Yanlu Xiong, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 124
Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity
Takumi Maruhashi, Daisuke Sugiura, Il‐mi Okazaki, et al.
Immunity (2022) Vol. 55, Iss. 5, pp. 912-924.e8
Open Access | Times Cited: 122
LAG3 associates with TCR–CD3 complexes and suppresses signaling by driving co-receptor–Lck dissociation
Clifford S. Guy, Diana M. Mitrea, Po-Chien Chou, et al.
Nature Immunology (2022) Vol. 23, Iss. 5, pp. 757-767
Open Access | Times Cited: 121
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Letong Cai, Yuchen Li, Jiaxiong Tan, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 119
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
Jin-Ling Huo, Yatao Wang, Wen-Jia Fu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 100
Melanoma Management: From Epidemiology to Treatment and Latest Advances
Joana Lopes, Cecília M. P. Rodrigues, Maria Manuela Gaspar, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4652-4652
Open Access | Times Cited: 92
The changing role of natural killer cells in cancer metastasis
Isaac S. Chan, Andrew J. Ewald
Journal of Clinical Investigation (2022) Vol. 132, Iss. 6
Open Access | Times Cited: 72
T Cell Exhaustion
Andrew Baessler, Dario A.A. Vignali
Annual Review of Immunology (2024) Vol. 42, Iss. 1, pp. 179-206
Closed Access | Times Cited: 62
Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials
Bin Li, Juan Jin, Duancheng Guo, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2858-2858
Open Access | Times Cited: 54
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 54
Novel targets for immune-checkpoint inhibition in cancer
Maxime Borgeaud, José Luís Sandoval, Michel Obéid, et al.
Cancer Treatment Reviews (2023) Vol. 120, pp. 102614-102614
Open Access | Times Cited: 53
Stimulus‐Responsive Copper Complex Nanoparticles Induce Cuproptosis for Augmented Cancer Immunotherapy
Fuzhen Hu, Jia Huang, Tiejun Bing, et al.
Advanced Science (2024) Vol. 11, Iss. 13
Open Access | Times Cited: 37
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Ronan J. Kelly, Blair V. Landon, Ali H. Zaidi, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1023-1034
Open Access | Times Cited: 31
Immune checkpoint inhibitors: breakthroughs in cancer treatment
Xueqing Kong, Jinyi Zhang, Shuwei Chen, et al.
Cancer Biology and Medicine (2024), pp. 1-11
Open Access | Times Cited: 18
Recent developments in immunotherapy for gastrointestinal tract cancers
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 15
Advances in Immunotherapy in Hepatocellular Carcinoma
Matthew B. Bloom, S. Podder, Hien Dang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 1936-1936
Open Access | Times Cited: 2
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
Christian Sordo‐Bahamonde, Seila Lorenzo‐Herrero, Ana Pilar González-Rodríguez, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2112-2112
Open Access | Times Cited: 84
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Wenjing Qian, Mingfang Zhao, Ruoyu Wang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 78
Tumor metastasis: Mechanistic insights and therapeutic interventions
Mengmeng Liu, Jing Yang, Bu-Shu Xu, et al.
MedComm (2021) Vol. 2, Iss. 4, pp. 587-617
Open Access | Times Cited: 76
The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer
Yaping Chen, Xiao Zheng, Changping Wu
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 72
Page 1 - Next Page

Scroll to top